var data={"title":"Midazolam: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Midazolam: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6581?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=midazolam-patient-drug-information\" class=\"drug drug_patient\">see &quot;Midazolam: Patient drug information&quot;</a> and <a href=\"topic.htm?path=midazolam-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Midazolam: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709086\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Respiratory depression and personnel/equipment for monitoring and resuscitation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Midazolam has been associated with respiratory depression and respiratory arrest, especially when used for sedation in noncritical care settings; airway obstruction, desaturation, hypoxia, and apnea have also been reported, most often when used concomitantly with other CNS depressants (eg, opioids). In some cases, where this was not recognized promptly and treated effectively, death or hypoxic encephalopathy has resulted. Midazolam should be used only in hospital or ambulatory care settings, including physicians' and dentists' offices, that can provide for continuous monitoring of respiratory and cardiac function (ie, pulse oximetry). Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation, and personnel trained in their use and skilled in airway management should be assured. For deeply sedated pediatric patients, a dedicated individual, other than the practitioner performing the procedure, should monitor the patient throughout the procedure.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Risks from concomitant use with opioids:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Individualization of dosage (injection):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Midazolam must never be used without individualization of dosage. The initial intravenous dose for sedation in adult patients may be as little as 1 mg, but should not exceed 2.5 mg in a healthy adult. Lower doses are necessary for older (over 60 years) or debilitated patients and in patients receiving concomitant opioids or other CNS depressants. The initial dose and all subsequent doses should always be titrated slowly; administer over at least 2 minutes and allow an additional 2 or more minutes to fully evaluate the sedative effect. The use of the 1 mg/mL formulation or dilution of the 1 mg/mL or 5 mg/mL formulation is recommended to facilitate slower injection. Doses of sedative medications in pediatric patients must be calculated on a mg/kg basis, and initial doses and all subsequent doses should always be titrated slowly. The initial pediatric dose of midazolam for sedation/anxiolysis/amnesia is age, procedure, and route dependent.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Neonates (injection):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Midazolam should not be administered by rapid injection in the neonatal population. Severe hypotension and seizures have been reported following rapid IV administration, particularly with concomitant use of fentanyl.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49990988\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Midazolam+SyrSpend SF PH4</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196443\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Midazolam Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196489\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Anticonvulsant, Benzodiazepine;</li>\n      <li>\n        Benzodiazepine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196447\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>The dose of midazolam needs to be individualized based on the patient's age, underlying diseases, and concurrent medications. Consider reducing dose by 20% to 50% in elderly, chronically ill, or debilitated patients and those receiving opioids or other CNS depressants (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Anesthesia:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Induction:</i> Adults &lt;55 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Unpremedicated patients: Initial: 0.3 to 0.35 mg/kg over 20 to 30 seconds; after 2 minutes, may repeat if necessary at ~25% of initial dose every 2 minutes, up to a total dose of 0.6 mg/kg in resistant cases.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Premedicated patients: Usual dosage range: 0.05 to 0.2 mg/kg (Barash 2009; Miller 2010). Use of 0.2 mg/kg administered over 5 to 10 seconds has been shown to safely produce anesthesia within 30 seconds (Samuelson 1981) and is recommended for ASA physical status P1 and P2 patients. When used with other anesthetic drugs (ie, co-induction), the dose is &lt;0.1 mg/kg (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">ASA physical status &gt;P3 or debilitation: Reduce dose by at least 20% (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Maintenance:</i> 0.05 mg/kg as needed (Miller 2010), or continuous infusion 0.015 to 0.06 mg/kg/<b>hour</b> (0.25 to 1 <b>mcg</b>/kg/minute) (Barash 2009; Miller 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sedation/anxiolysis/amnesia (preoperative/procedural):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Healthy adults &lt;60 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>IM:</i> 0.07 to 0.08 mg/kg 30 to 60 minutes prior to surgery/procedure; usual dose: 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>IV:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Initial: Some patients respond to doses as low as 1 mg; no more than 2.5 mg should be administered over a period of at least 2 minutes. Additional doses of midazolam may be administered after at least a 2-minute waiting period and evaluation of sedation after each dose increment. A total dose &gt;5 mg is generally not needed.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Premedicated patients: Reduce initial dose by 30%</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Maintenance: 25% of dose used to reach sedative effect</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults &ge;60 years, debilitated, or chronically ill: Refer to geriatric dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intranasal (off-label route):</i> 0.1 mg/kg; administer 15 minutes prior to surgery/procedure (Uygur-Bayrami&ccedil;li 2002). <b>Note:</b> Use 5 mg/mL injectable solution to deliver dose. Due to the low pH of the solution, burning upon administration is likely to occur (Bailey 2017; Bozkurt 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>IV (off-label dosing):</i> Initial: 0.5 to 2 mg over at least 2 minutes; slowly titrate to effect by repeating doses every 2 to 3 minutes if needed; usual total dose: 2.5 to 5 mg (ASGE [Waring 2003])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sedation in mechanically-ventilated patients:</b> <b>Note</b>: Nonbenzodiazepine sedation may be preferred (SCCM [Barr 2013]). IV: Initial: 0.01 to 0.05 mg/kg (~0.5 to 4 mg); may repeat at 10- to 15-minute intervals until adequate sedation achieved; maintenance infusion: 0.02 to 0.1 mg/kg/<b>hour</b> (0.3 to 1.7 <b>mcg</b>/kg/minute). Titrate to reach desired level of sedation. Titration to maintain a light rather than a deep level of sedation is recommended unless clinically contraindicated (SCCM [Barr 2013]). May consider a trial of daily awakening; if agitated after discontinuation of drip, then restart at 50% of the previous dose (Kress 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Palliative sedation (off-label use): Note: </b>Use of midazolam in this setting should be done in close consult with or by an experienced palliative care provider. Ensure that flumazenil is readily available in the case of inadvertent overdose (ESMO [Cherney 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV, SubQ:</i> Continuous infusion: Initial: 0.5 to 1 mg/hour; may increase as needed. Usual dosage range: 1 to 20 mg/hour; may also intermittently administer 1 to 5 mg during infusion as needed (ESMO [Cherney 2014]). Some have recommended an initial bolus dose of 5 to 10 mg (size of dose depending on patient weight, age, and degree of debility) (Johanson 1993).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Status epilepticus (off-label use): </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IM:</i> 10 mg once (AES [Glauser 2016]) <b>or </b>0.2 mg/kg once (maximum dose: 10 mg) (NCS [Brophy 2012]). <b>Note:</b> Midazolam IM is the preferred treatment in patients <i>without</i> IV access. Buccal and intranasal midazolam administration has also been used in patients without IV access, although these off-label routes are less well studied (AES [Glauser 2016]; Bailey 2017; deHaan 2010; NCS [Brophy 2012]; Scheepers 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prehospital status epilepticus: IM: 10 mg once; has been administered by paramedics when convulsions last &gt;5 minutes <b>or</b> if convulsions are occurring after having intermittent seizures without regaining consciousness for &gt;5 minutes (Silbergleit 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intranasal:</i> Limited data available: 0.2 mg/kg (NCS [Brophy 2012]). <b>Note:</b> Use 5 mg/mL injectable concentrated solution to deliver dose. Due to the low pH of the solution, burning upon administration is likely to occur (Bailey 2017; Bozkurt 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Buccal:</i> Limited data available: 0.5 mg/kg (NCS [Brophy 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Status epilepticus, refractory (off-label use):</b> IV: <b>Note:</b> Mechanical ventilation and cardiovascular monitoring required; titrate dose to cessation of electrographic seizures or burst suppression (NCS [Brophy 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neurocritical Care Society recommendations</i>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 0.2 mg/kg followed by a continuous infusion (NCS [Brophy 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion: 0.05 to 2 mg/kg/<b>hour</b> (0.83 to 33.2 <b>mcg</b>/kg/minute) titrated to cessation of electrographic seizures or burst suppression. If patient experiences breakthrough status epilepticus while on the continuous infusion, administer a bolus of 0.1 to 0.2 mg/kg and increase infusion rate by 0.05 to 0.1 mg/kg/<b>hour</b> (0.83 to 1.66 <b>mcg</b>/kg/minute) every 3 to 4 hours (NCS [Brophy 2012]). Doses up to 2.9 mg/kg/hour have been described in the literature (Fernandez 2014). <b>Note:</b> A period of at least 24 to 48 hours of electrographic control is recommended prior to withdrawing the continuous infusion; withdraw gradually to prevent recurrent status epilepticus.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196467\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=midazolam-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Midazolam: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The dose of midazolam needs to be individualized based on the patient's age, underlying diseases, and concurrent medications. Decrease dose (by ~30%) if opioids or other CNS depressants are administered concomitantly. Children &lt;6 years may require higher doses and closer monitoring than older children; in children with obesity, calculate dose based on ideal body weight.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Sedation/Anxiolysis/Amnesia (preoperative/procedural):</b> Infants &ge;6 months, Children, and Adolescents &le;16 years:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> 0.25 to 0.5 mg/kg (maximum: 20 mg) as a single dose 20 to 30 minutes prior to procedure. Children &lt;6 years or less cooperative patients may require as much as 1 mg/kg as a single dose; 0.25 mg/kg may suffice for children 6 to 16 years of age or for cooperative patients. Doses of 0.5 to 0.75 mg/kg administered 20 to 30 minutes prior to procedure have also been suggested; however, doses above 0.5 mg/kg typically do not improve the sedative and anxiolytic effects but increase side effects during recovery (Bozkurt 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IM:</i> 0.1 to 0.15 mg/kg 30 to 60 minutes before surgery or procedure; range: 0.05 to 0.15 mg/kg; doses up to 0.5 mg/kg have been used in more anxious patients; maximum total dose: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intranasal (off-label route):</i> 0.2 to 0.5 mg/kg (maximum total dose: 10 mg or 5 mg per nare); may be administered 10 to 20 minutes prior to procedure (Bozkurt 2007; Chiaretti 2011). <b>Note:</b> Use 5 mg/mL injectable concentrated solution to deliver dose. Due to the low pH of the solution, burning upon administration is likely to occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;6 months: Limited information is available in nonintubated infants; dosing recommendations not clear; infants &lt;6 months are at higher risk for airway obstruction and hypoventilation; titrate dose in small increments to desired effect</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants 6 months to Children 5 years: Initial: 0.05 to 0.1 mg/kg; total dose of 0.6 mg/kg may be required; maximum total dose: 6 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 12 years: Initial: 0.025 to 0.05 mg/kg; total doses of 0.4 mg/kg may be required; maximum total dose: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 12 to 16 years: Refer to adult dosing; maximum total dose: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Rectal (off-label route):</i> 0.5 to 0.75 mg/kg (maximum: 20 mg) as a single dose 20 to 30 minutes prior to procedure (Bozkurt 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Sedation in mechanically-ventilated patients (off-label dosing):</b> Infants, Children, and Adolescents: IV: Loading dose: 0.05 to 0.2 mg/kg, followed by initial continuous infusion: 0.06 to 0.12 mg/kg/<b>hour</b> (1 to 2 <b>mcg</b>/kg/minute); range in clinical trials: 0.024 to 0.564 mg/kg/<b>hour</b> (0.4 to 9.4 <b>mcg</b>/kg/minute) (Hartman 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Seizures (off-label use):</b> Children and Adolescents: IM: 0.2 mg/kg (maximum dose: 6 mg); may repeat every 10 to 15 minutes (AAP [Hegenbarth 2008]; Chamberlain 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Status epilepticus (off-label use):</b> Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IM (AES [Glauser 2016]; NCS [Brophy 2012]): </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;13 kg: Not evaluated</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">13 to 40 kg: 5 mg once</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;40 kg: 10 mg once</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Midazolam IM is the preferred treatment in patients <i>without</i> IV access .Buccal and intranasal midazolam administration have also been used in patients without IV access, although those off-label routes are less well studied (NCS [Brophy 2012]; AES [Glauser 2016]). For prehospital status epilepticus, midazolam IM has been be administered by paramedics when convulsions last &gt;5 minutes or if convulsions are occurring after having intermittent seizures without regaining consciousness for &gt;5 minutes (Silbergleit 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intranasal:</i> Limited data available: 0.2 mg/kg (NCS [Brophy 2012]). <b>Note:</b> Use 5 mg/mL injectable concentrated solution to deliver dose (Ljungman 2000). Due to the low pH of the solution, burning upon administration is likely to occur (Bozkurt 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Buccal:</i> Limited data available: 0.5 mg/kg (NCS [Brophy 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Status epilepticus, refractory (off-label use):</b> Infants, Children, and Adolescents: IV: <b>Note:</b> Mechanical ventilation and cardiovascular monitoring required; titrate dose to cessation of electrographic seizures or burst suppression (NCS [Brophy 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Neurocritical Care Society recommendations</i> (NCS [Brophy 2012]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 0.2 mg/kg followed by a continuous infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion: 0.05 to 2 mg/kg/<b>hour</b> (0.83 to 33.2 <b>mcg</b>/kg/minute) titrated to cessation of electrographic seizures or burst suppression. If patient experiences breakthrough status epilepticus while on the continuous infusion, administer a bolus of 0.1 to 0.2 mg/kg and increase infusion rate by 0.05 to 0.1 mg/kg/<b>hour</b> (0.83 to 1.66 <b>mcg</b>/kg/minute) every 3 to 4 hours. <b>Note:</b> A period of at least 24 to 48 hours of electrographic control is recommended prior to withdrawing the continuous infusion; withdraw gradually to prevent recurrent status epilepticus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>American Academy of Pediatrics recommendations</i> (AAP [Hegenbarth 2008]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Loading dose: 0.15 to 0.2 mg/kg followed by a continuous infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous infusion: 1 mcg/kg/minute titrated every 15 minutes by increments of 1 mcg/kg/minute until the cessation of seizures (maximum: 5 mcg/kg/minute)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196448\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: The dose of midazolam needs to be individualized based on the patient's age, underlying diseases, and concurrent medications. Consider reducing dose by 20% to 50% in elderly, chronically ill, or debilitated patients and those receiving opioids or other CNS depressants (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n      <b>Anesthesia:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction: Adults &ge;55 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Unpremedicated patients: Initial: 0.3 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Premedicated patients: Reduce dose by at least 20% (Miller 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sedation/Anxiolysis/Amnesia (preoperative/procedural):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IM: 2 to 3 mg (or 0.02 to 0.05 mg/kg) 30 to 60 minutes prior to surgery/procedure; some may only require 1 mg if anticipated intensity and duration of sedation is less critical.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Initial: </i>Some patients respond to doses as low as 1 mg; no more than 1.5 mg should be administered over a period of at least 2 minutes. Additional doses of no more than 1 mg over at least 2 minutes may be administered after at least a 2-minute waiting period and evaluation of sedation after each dose increment. A total dose of &gt;3.5 mg is generally not needed.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Premedicated patients: Reduce initial dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Maintenance:</i> 25% of dose used to reach sedative effect</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations (off-label dosing): IV: Initial: 0.5 to 2 mg administered over at least 2 minutes (smaller doses may be used in the elderly); slowly titrate to effect by repeating doses every 2 to 3 minutes if needed; usual total dose: 2.5 to 5 mg (ASGE [Waring 2003])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196449\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution; half-life of midazolam and metabolites may be prolonged. Patients with renal failure receiving a continuous infusion cannot adequately eliminate the active hydroxylated metabolites (eg, 1-hydroxymidazolam) contributing to prolonged sedation sometimes for days after discontinuation (Spina 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intermittent hemodialysis: Supplemental dose is not necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous venovenous hemofiltration (CVVH): Unconjugated 1-hydroxymidazolam not effectively removed; 1-hydroxymidazolamglucuronide effectively removed; sieving coefficient = 0.45 (Swart 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peritoneal dialysis: Significant drug removal is unlikely based on physiochemical characteristics.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13134499\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no dosage adjustments provided in the manufacturer's labeling;  use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Single dose (eg, induction): No dosage adjustment recommended; patients with hepatic impairment may be more sensitive compared to patients without hepatic impairment; anticipate longer duration of action (MacGilchrist 1986; Trouvin 1988).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multiple dosing or continuous infusion: Expect longer duration of action and accumulation; based on patient response, dosage reduction likely to be necessary (Trouvin 1988).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196415\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/2 mL (2 mL); 5 mg/5 mL (5 mL); 10 mg/10 mL (10 mL); 5 mg/mL (1 mL); 10 mg/2 mL (2 mL); 25 mg/5 mL (5 mL); 50 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/2 mL (2 mL); 5 mg/5 mL (5 mL); 5 mg/mL (1 mL); 10 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/100 mL (100 mL); 25 mg/100 mL (100 mL); 50 mg/100 mL (100 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/2 mL in NaCl 0.9% (2 mL [DSC]); 4 mg/2 mL in NaCl 0.9% (2 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Midazolam+SyrSpend SF PH4: 1 mg/mL (120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Syrup, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/mL (118 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196399\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50027222\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Midazolam+SyrSpend SF PH4 oral suspension is a compounding kit. Refer to manufacturer's labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196491\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-IV</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196419\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal (off-label route):<b> Note:</b> Due to the low pH of the solution, burning upon administration is likely to occur. Use of an atomizer, such as the MAD 300 Mucosal Atomizer which attaches to a tuberculin syringe, can reduce irritation. If possible, based upon dose to be administered, use higher concentration injectable solution to minimize volume administered intranasal. Smaller volume will reduce irritation and swallowing of administered dose. The maximum recommended dose volume per nare is 1 mL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Using the 5 mg/mL injectable solution, draw up desired dose with a 1 to 3 mL needleless syringe; may attach a nasal mucosal atomization device prior to delivering dose. Deliver half of the total dose volume (of the 5 mg/mL concentration) into the first nare using the atomizer device or by dripping slowly into nostril, then deliver the other half of the dose into the second nare.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Do not mix with any liquid (such as grapefruit juice) prior to administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Do <b>not</b> administer intraarterially.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Administer undiluted deep IM into large muscle</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: For procedural sedation/anxiolysis/amnesia, administer by slow IV injection over at least 2 minutes using a concentration of 1 mg/mL or a dilution of the 1 or 5 mg/mL concentrations. For induction of anesthesia, administer IV bolus over 5 to 15 seconds (Miller 2010). For other clinical situations (eg, sedation in the mechanically-ventilated patient), a continuous infusion may also be administered.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472924\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 100 mg in 100 mL (concentration: 1 mg/mL) of D<sub>5</sub>W or NS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472925\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 0.5 mg/mL <b>or</b> 1 mg/mL  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196418\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anesthesia:</b> IV: Induction of general anesthesia before administration of other anesthetic agents; maintenance of anesthesia as a component of balanced anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sedation/anxiolysis/amnesia (preoperative/procedural):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Preoperative sedation, anxiolysis, and amnesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Sedation, anxiolysis, and amnesia prior to or during diagnostic, therapeutic, or endoscopic procedures, or prior to surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Sedation, anxiolysis, and amnesia in children prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sedation for mechanically-ventilated patients:</b> IV: Sedation of intubated and mechanically-ventilated patients as a component of anesthesia or during treatment in a critical care setting by continuous IV infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730634\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Seizures (children/adolescents); Status epilepticus (children/adolescents/adults); Status epilepticus, refractory (adults); Status epilepticus, refractory (children/adolescents); Palliative sedation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196498\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Versed may be confused with VePesid, Vistaril</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication (IV, oral administration for sedation in children) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196406\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">As reported in adults unless otherwise noted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Respiratory: Bradypnea, decreased tidal volume</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypotension (children: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Drowsiness (1%), headache (1%), seizure-like activity (children: 1%), drug dependence (physical and psychological dependence with prolonged use), myoclonus (preterm infants), severe sedation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Hiccups (adults: 4%; children: 1%), nausea (3%), vomiting (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (IM: &le;4%, IV: &le;5%; severity less than diazepam), pain at injection site (IM: &le;4%, IV: &le;5%; severity less than diazepam)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Nystagmus (children: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Apnea (children: 3%), cough (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Paradoxical reaction (children: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Acidic taste, agitation, amnesia, bigeminy, bradycardia, bronchospasm, confusion, delirium (emergence), dyspnea, euphoria, hallucination, hyperventilation, laryngospasm, sialorrhea, skin rash, tachycardia, ventricular premature contractions, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196422\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to midazolam or any component of the formulation; intrathecal or epidural injection of parenteral forms containing preservatives (ie, benzyl alcohol); use in premature infants for parenteral forms containing benzyl alcohol; acute narrow-angle glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Concurrent use of oral midazolam with protease inhibitors (atazanavir, atazanavir-cobicistat, darunavir, indinavir, lopinavir-ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir); concurrent use of oral or injectable midazolam with fosamprenavir.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for benzodiazepines is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to benzodiazepines; acute pulmonary insufficiency; severe chronic obstructive pulmonary disease.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196403\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia (Nelson 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiorespiratory effects: <b>[US Boxed Warning]: Has been associated with respiratory depression and respiratory arrest, especially when used for sedation in noncritical care settings; airway obstruction, desaturation, hypoxia, and apnea have also been reported, most often when used concomitantly with other CNS depressants (eg, opioids). In some cases, death or hypoxic encephalopathy resulted. Use only in hospital or ambulatory care settings that provide for continuous monitoring of respiratory and cardiac function (ie, pulse oximetry). Immediate availability of resuscitative drugs and age- and size-appropriate equipment for bag/valve/mask ventilation and intubation, and personnel trained in their use and skilled in airway management should be assured. For deeply sedated patients, a dedicated individual, other than the practitioner performing the procedure, should monitor the patient throughout the procedure.</b> Risk of cardiorespiratory adverse events is increased in patients with abnormal airway anatomy, cyanotic congenital heart disease, sepsis or severe pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). A minimum of 1 day should elapse after midazolam administration before attempting these tasks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: May cause hypotension, particularly in pediatric patients or patients with hemodynamic instability. Hypotension may occur more frequently in patients who have received opioid analgesics.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Paradoxical reactions: Paradoxical reactions, including agitation, hyperactive or aggressive behavior, involuntary movements (including tonic/clonic movements and muscle tremor) and combativeness have been reported with benzodiazepines. Consideration should be given to the possibility of cerebral hypoxia or true paradoxical reactions. Should such reactions occur, the response to each dose of midazolam and all other drugs, including local anesthetics, should be evaluated before proceeding. May consider treatment with flumazenil (Massanari 1997).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: Use IV midazolam with caution in patients with uncompensated acute illnesses, such as severe fluid or electrolyte disturbances.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with heart failure. Adverse hemodynamic events have been reported in pediatric patients with cardiovascular instability; avoid rapid IV administration in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use with caution in patients with glaucoma; contraindicated in patients with acute narrow angle glaucoma; may use in patients with open-angle glaucoma only if receiving appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; half-life of midazolam and metabolites may be prolonged.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use with caution in patients with respiratory disease (eg, COPD); these patients may be sensitive to the respiratory depressant effects of midazolam.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concomitant use with opioids: <b>[US Boxed Warning]: Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution in debilitated patients; decreased dosages recommended. These patients take longer to recover completely after midazolam administration for the induction of anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; decreased dosages recommended. These patients take longer to recover completely after midazolam administration for the induction of anesthesia. Use of oral midazolam is not recommended in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury (Nelson 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obese patients: Use benzodiazepines with caution in obese patients; may have prolonged action when discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Injection: <b>[US Boxed Warning]: Do not administer by rapid IV injection in neonates; severe hypotension and seizures have been reported following rapid IV administration, particularly with concomitant fentanyl use.</b> Neonates are also vulnerable to profound and/or prolonged respiratory effects of midazolam.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Pediatric patients with cardiac or respiratory compromise may be sensitive to the respiratory depressant effect of midazolam. Pediatric patients undergoing procedures involving the upper airway (eg, upper endoscopy, dental care) are vulnerable to episodes of desaturation and hypoventilation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric neurotoxicity: In pediatric and neonatal patients &lt;3 years and patients in third trimester of pregnancy (ie, times of rapid brain growth and synaptogenesis), the repeated or lengthy exposure to sedatives or anesthetics during surgery/procedures may have detrimental effects on child or fetal brain development and may contribute to various cognitive and behavioral problems. Epidemiological studies in humans have reported various cognitive and behavioral problems, including neurodevelopmental delay (and related diagnoses), learning disabilities, and ADHD. Human clinical data suggest that single, relatively short exposures are not likely to have similar negative effects. No specific anesthetic/sedative has been found to be safer. For elective procedures, risk versus benefits should be evaluated and discussed with parents/caregivers/patients; critical surgeries should not be delayed (FDA 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&quot;gasping syndrome&quot;) in neonates; the &quot;gasping syndrome&quot; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection: <b>[US Boxed Warning]: Midazolam must never be used without individualization of dosage. The initial IV dose for sedation in adults may be as little as 1 mg, but should not exceed 2.5 mg in a healthy adult. Lower doses are necessary for older (&gt;60 years of age) or debilitated patients and in patients receiving concomitant opioids or other CNS depressants. The initial dose and all subsequent doses should always be titrated slowly; administer over at least 2 minutes and allow an additional 2 or more minutes to fully evaluate the sedative effect. The use of the 1 mg/mL formulation or dilution of the 1 mg/mL or 5 mg/mL formulation is recommended to facilitate slower injection. Doses of sedative medications in pediatric patients must be calculated on a mg/kg basis, and initial doses and all subsequent doses should always be titrated slowly. The initial pediatric dose of midazolam for sedation/anxiolysis/amnesia is age, procedure, and route dependent.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties. Does not protect against increases in intracranial pressure, heart rate, and/or blood pressure during intubation. Do not use in shock, coma, or acute alcohol intoxication with depression of vital signs. Avoid intra-arterial administration or extravasation of parenteral formulation. Use during upper airway procedures (ie, endoscopy, dental care) may increase risk of hypoventilation. Prolonged responses have been noted following extended administration by continuous infusion (possibly due to metabolite accumulation) or in the presence of drugs which inhibit midazolam metabolism. Oral midazolam is intended for use in monitored settings only and not for chronic or home use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tolerance: Midazolam is a short half-life benzodiazepine and may be of benefit in patients where a rapidly and short-acting agent is desired (acute agitation). Duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance develops to the sedative and anticonvulsant effects. It does not develop to the anxiolytic effects (Vinkers 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: Withdrawal symptoms (convulsions, hallucinations, tremor, abdominal and muscle cramps, vomiting and sweating) may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196481\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2B6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196408\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9650&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of Midazolam. Management: Oral midazolam contraindicated with antihepaciviral combination products. When used with intravenous midazolam, monitor for increased midazolam effects (eg, sedation, respiratory depression) and consider using a reduced midazolam dose.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: May increase the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of Midazolam.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of Midazolam. Management: Oral midazolam use is contraindicated with cobicistat-containing products.  IV midazolam should be used with caution, close monitoring, and consideration of lower IV midazolam doses.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ginkgo Biloba: May decrease the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of Midazolam. Management: Oral midazolam is contraindicated.  Use intravenous midazolam with great caution in patients receiving itraconazole, employing reduced initial doses whenever possible and monitoring closely for enhanced and prolonged effects.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): May increase the serum concentration of Midazolam.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May increase the serum concentration of Midazolam. Management: Consider an alternative less likely to interact. Azithromycin is likely a lower-risk macrolide, and benzodiazepines less dependent on CYP3A metabolism (e.g., lorazepam, oxazepam) are similarly less likely to interact.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melatonin: May enhance the sedative effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone.  Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propofol: Midazolam may increase the serum concentration of Propofol. Propofol may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May increase the serum concentration of Midazolam. Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roxithromycin: May increase the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teduglutide: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Midazolam. Management: Use of oral midazolam with telaprevir is contraindicated.  IV midazolam use may pose a lower risk, but dose reductions should be considered and patients should be monitored closely for signs/symptoms of toxicity.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofisopam: May increase the serum concentration of Midazolam.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196439\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice may increase serum concentrations of midazolam. Management: Avoid concurrent use of grapefruit juice with oral midazolam.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196410\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196425\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have not been observed in animal reproduction studies. Midazolam has been found to cross the human placenta and can be detected in the serum of the umbilical vein and artery, as well as the amniotic fluid. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) have been reported with some benzodiazepines (Bergman 1992, Iqbal 2002, Wikner 2007).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Based on animal data, repeated or prolonged use of general anesthetic and sedation medications that block N-methyl-D-aspartate (NMDA) receptors and/or potentiate gamma-aminobutyric acid (GABA) activity may affect brain development. Human fetuses may be most vulnerable during the third trimester. Until additional information is available, the benefits and risks of maternal treatment with midazolam during pregnancy should be evaluated, especially for procedures lasting more than 3 hours. The ACOG recommends that pregnant women should not be denied medically indicated surgery or procedures, regardless of trimester. If the procedure is elective, it should be delayed until after delivery (ACOG 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11229384\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Midazolam and hydroxymidazolam are present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of midazolam is 0.35% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 30 mg.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, breastfeeding is considered acceptable when an RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The RID of midazolam was calculated using a milk concentration of 0.0001 mg/mL (30 nmol/L), providing an estimated daily infant dose via breast milk of 0.0015 mg/kg/day. This milk concentration was obtained following accidental maternal administration of two oral doses of midazolam 15 mg (total dose: 30 mg) (Matheson 1990). In most reports, midazolam and hydroxymidazolam concentrations in breast milk are below the limit of quantification 4 hours after a single dose (Koitabashi 1997; Matheson 1990).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">CNS depression was reported in infants following exposure to benzodiazepines via breast milk (study included exposures to midazolam) (Kelly 2012). The manufacturer recommends that caution be exercised when administering midazolam to breastfeeding women. Available guidelines suggest waiting for &ge;4 hours after a maternal dose of midazolam to continue breastfeeding (Shergill 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196426\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid grapefruit juice with oral syrup.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196412\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Level of sedation, respiratory rate, heart rate, blood pressure, oxygen saturation (ie, pulse oximetry).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Critically-ill patients: Monitor depth of sedation with either the Richmond Agitation-Sedation Scale (RASS) or Sedation-Agitation Scale (SAS) (SCCM [Barr 2013])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196402\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors (Brunton 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196421\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: IM: Sedation: Children: Within 5 minutes; Adults: ~15 minutes; IV: 3 to 5 minutes; Oral: 10 to 20 minutes; Intranasal: Children: 5.55 &plusmn; 2.22 minutes (Lee-Kim 2004); Adults: Within 5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peak effect: IM: Children: 15 to 30 minutes; Adults: 30 to 60 minutes; IV: 3 to 5  minutes; Intranasal: Children: 10 minutes (al-Rakaf 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: IM: Up to 6 hours; Mean: 2 hours; Intranasal: Children: 23.1 minutes (Chiaretti 2011); IV: Single dose: &lt;2 hours (dose-dependent) (Fragen 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: IM: Rapid, complete; Oral, Intranasal: Rapid (Lee-Kim 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Widely distributed in body including CSF; V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm infants (n=24; GA: 26 to 34 weeks; PNA: 3 to 11 days): Median: 1.1 L/kg (range: 0.4 to 4.2 L/kg) (de Wildt 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 6 months to 16 years: 1.24 to 2.02 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 1 to 3.1 L/kg; increased in females, elderly, and obesity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~97%, primarily albumin; in patients with cirrhosis, protein binding is reduced with a free fraction of ~5% (Trouvin 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic CYP3A4; 60% to 70% of biotransformed midazolam is the active metabolite 1-hydroxy-midazolam (or alpha-hydroxymidazolam)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: 40% to 50% (Kanto 1985), ~36% (children); IM: &gt;90%; Intranasal: Children: ~60%; Rectal: Children: ~40% to 65% (mean: 52%) (Clausen 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prolonged in cirrhosis, congestive heart failure, obesity, renal failure, and elderly.<b> Note:</b> In patients with renal failure, reduced elimination of active hydroxylated metabolites leads to drug accumulation and prolonged sedation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm infants (n=24; GA: 26 to 34 weeks; PNA: 3 to 11 days): Median: 6.3 hours (range: 2.6 to 17.7 hours) (de Wildt 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: 4 to 12 hours; seriously ill neonates: 6.5 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: IV: 2.9 to 4.5 hours; Syrup: 2.2 to 6.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 3 hours (range: 1.8 to 6.8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: IM: 0.5 to 1 hour; Oral: 0.17 to 2.65 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: IV: Urine (primarily as metabolites); Oral: Urine (~90% within 24 hours; primarily [60% to 70%] as glucuronide conjugates of the hydroxylated metabolites; &lt;0.03% as unchanged drug); feces (~2% to 10% over 5 days) (Kanto 1985; Smith 1981)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Preterm infants (n=24; GA: 26 to 34 weeks; PNA: 3 to 11 days): Median: 1.8 mL/minute/kg (range: 0.7 to 6.7 mL/minute/kg) (de Wildt 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates &lt;39 weeks GA: 1.17 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates &gt;39 weeks GA: 1.84 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Seriously ill neonates: 1.2 to 2 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &gt;3 months: 9.1 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &gt;1 year: 3.2 to 13.3 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Healthy adults: 4.2 to 9 mL/minute/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults with acute renal failure: 1.9 mL/minute/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323409\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Midazolam HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/2 mL (2 mL): $1.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (5 mL): $1.22</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (1 mL): $3.01</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/10 mL (10 mL): $2.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/2 mL (2 mL): $2.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/5 mL (5 mL): $4.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/10 mL (10 mL): $7.08</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Midazolam HCl-NaCl (PF) Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/100 mL 0.9% (100 mL): $20.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 0.9% (100 mL): $47.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Midazolam HCl-Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/100 mL 0.9% (100 mL): $18.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/100 mL 0.9% (100 mL): $31.07</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Midazolam+SyrSpend SF PH4 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (120 mL): $437.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Syrup</b> (Midazolam HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (118 mL): $81.25</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196427\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anespar (ID);</li>\n      <li>Buccolam (ES, GB, IE, IL, MT);</li>\n      <li>Dalam (AR, JO, PY);</li>\n      <li>Diormicum (SV);</li>\n      <li>Domi (MY);</li>\n      <li>Doricum (VE);</li>\n      <li>Dormicum (AE, AR, AT, BB, BD, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, IQ, IR, IS, JM, JO, KE, KR, KW, LB, LK, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NI, NL, OM, PA, PH, PK, PL, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VN, YE, ZA, ZM, ZW);</li>\n      <li>Dormicum[inj.] (HR);</li>\n      <li>Dormid (PH);</li>\n      <li>Dormilat (BD);</li>\n      <li>Dormitol (LK);</li>\n      <li>Dormizol (PH);</li>\n      <li>Dormonid (BR, CL, PE);</li>\n      <li>Fulsed (CN, IN, VN);</li>\n      <li>Hipnoz (ID);</li>\n      <li>Hypnofast (HK);</li>\n      <li>Hypnovel (AU, BE, CO, FR, GB, IE, NZ);</li>\n      <li>Hypozam (PH);</li>\n      <li>Ipnovel (IT);</li>\n      <li>Midacum (ZA);</li>\n      <li>Midafresa (JP);</li>\n      <li>Midazo (TW);</li>\n      <li>Midolam (IL);</li>\n      <li>Midozor (MX);</li>\n      <li>Miloz (ID);</li>\n      <li>Mizolam (BD, MY);</li>\n      <li>Nok (BD);</li>\n      <li>Omida (TW);</li>\n      <li>Relacum (MX);</li>\n      <li>Sedacum (ID, LK, PH);</li>\n      <li>Sedoz (PH);</li>\n      <li>Sopnil (BD);</li>\n      <li>Uzolam (TW);</li>\n      <li>Versed (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abernathy DR and Greenblatt DJ, &ldquo;Drug Disposition in Obese Humans. An Update,&rdquo; <i>Clin Pharmacokinet</i>, 1986, 11(3):199-213.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 474: nonobstetric surgery during pregnancy. <i>Obstet Gynecol</i>. 2011;117(2, pt 1):420-421. doi:10.1097/AOG.0b013e31820eede9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/21252774/pubmed\" target=\"_blank\" id=\"21252774\">21252774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adrian ER, &ldquo;Intranasal Versed&reg;: The Future of Pediatric Conscious Sedation,&rdquo; <i>Pediatr Nurs</i>, 1994, 20(3):287-92.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Allonen H, Ziegler, G, and Klotz U, &ldquo;Midazolam Kinetics,&rdquo; <i>Clin Pharmacol Ther</i>, 1981, 30(5):653-61.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    al-Rakaf H, Bello LL, Turkustani A, et al, &quot;Intra-Nasal Midazolam in Conscious Sedation of Young Paediatric Dental Patients,&quot; <i>Int J Paediatr Dent</i>, 2001, 11(1):33-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11309871/pubmed\" target=\"_blank\" id=\"11309871\">11309871</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arcos J, &ldquo;Midazolam-Induced Ventricular Irritability,&rdquo; <i>Anesthesiology</i>, 1987, 67(4):612.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ashton H, &ldquo;Guidelines for the Rational Use of Benzodiazepines. When and What to Use,&rdquo; <i>Drugs</i>, 1994, 48(1):25-40.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28259526\"></a>Bailey AM, Baum RA, Hom K, et al. Review of intranasally administered medications for use in the emergency department. <i>J Emerg Med</i>. 2017;<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/28259526/pubmed\" target=\"_blank\" id=\"28259526\">28259526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey PL, Pace NL, Ashburn MA, et al, &ldquo;Frequent Hypoxemia and Apnea After Sedation With Midazolam and Fentanyl,&rdquo; <i>Anesthesiology</i>, 1990, 73(5):826-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/2122773/pubmed\" target=\"_blank\" id=\"2122773\">2122773</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barash PG, Cullen BF, Stoelting RK, et al, eds, <i>Clinical Anesthesia</i>, 6th ed, Philadelphia, PA; Lippincott Williams &amp; Wilkins, 2009.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barr J, Fraser GL, Puntillo K, et al, &ldquo;Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the Intensive Care Unit,&rdquo; <i>Crit Care Med</i>, 2013, 41(1):263-306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/23269131/pubmed\" target=\"_blank\" id=\"23269131\">23269131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bergman U, Rosa FW, Baum C, et al, &quot;Effects of Exposure to Benzodiazepine During Fetal Life,&quot; <i>Lancet</i>, 1992, 340(8821):694-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/1355799/pubmed\" target=\"_blank\" id=\"1355799\">1355799</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Booker PD, Beechey A, and Lloyd-Thomas AR, &ldquo;Sedation of Children Requiring Artificial Ventilation Using an Infusion of Midazolam,&rdquo; <i>Br J Anaesth</i>, 1986, 58(10):1104-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bozkurt P, &quot;Premedication of the Pediatric Patient - Anesthesia for the Uncooperative Child,&quot; <i>Curr Opin Anaesthesiol</i>, 2007, 20(3):211-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/17479023/pubmed\" target=\"_blank\" id=\"17479023\">17479023</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22528274\"></a>Brophy GM, Bell R, Claassen J, et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. <i>Neurocrit Care</i>. 2012;17(1):3-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/22528274/pubmed\" target=\"_blank\" id=\"22528274\">22528274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brunton LL, Chabner BA, Knollmann BC, eds. <i>Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics</i>. 12th ed. New York, NY: McGraw-Hill Medical; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Burtin P, Jacqz-Aigrain E, Girard P, et al, &ldquo;Population Pharmacokinetics of Midazolam in Neonates,&rdquo; <i>Clin Pharmacol Ther</i>, 1994, 56(6 Pt 1):615-25.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9127414\"></a>Chamberlain JM, Altieri AM, Futterman C, Young GM, Ochsenschlager DW, Waisman Y. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. <i>Pediatr Emerg Care</i>. 1997;13(2):92-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/9127414/pubmed\" target=\"_blank\" id=\"9127414\">9127414</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25210083\"></a>Cherney NI. ESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation. Ann Oncol. 2014;25(Suppl 3):iii143-152.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/25210083/pubmed\" target=\"_blank\" id=\"25210083\">25210083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chiaretti A, Barone G, Rigante D, et al, &quot;Intranasal Lidocaine and Midazolam for Procedural Sedation in Children,&quot; <i>Arch Dis Child</i>, 2011, 96(2):160-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/21030365/pubmed\" target=\"_blank\" id=\"21030365\">21030365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11571331\"></a>Claassen J, Hirsch LJ, Emerson RG, Bates JE, Thompson TB, Mayer SA. Continuous EEG monitoring and midazolam infusion for refractory nonconvulsive status epilepticus. <i>Neurology</i>. 2001;57(6):1036-1042.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11571331/pubmed\" target=\"_blank\" id=\"11571331\">11571331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clausen TG, Wolff J, Hansen PB, et al. Pharmacokinetics of midazolam and alpha-hydroxy-midazolam following rectal and intravenous administration. <i>Br J Clin Pharmacol</i>. 1988;25(4):457-463.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/3382589/pubmed\" target=\"_blank\" id=\"3382589\">3382589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davis PJ, Tome JA, and McGowan FX Jr, &ldquo;Preanesthetic Medication With Intranasal Midazolam for Brief Surgical Procedures,&rdquo; <i>Anesthesiology</i>, 1995, 82(1):2-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19817813\"></a>de Haan GJ, van der Geest P, Doelman G, et al. A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations. <i>Epilepsia.</i> 2010;51(3):478-482.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/19817813/pubmed\" target=\"_blank\" id=\"19817813\">19817813</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23353941\"></a>Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. <i>Crit Care Med</i>. 2013;41(2):580-637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/23353941/pubmed\" target=\"_blank\" id=\"23353941\">23353941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11753268\"></a>de Wildt SN, Kearns GL, Hop WC, et al. Pharmacokinetics and metabolism of intravenous midazolam in preterm infants. <i>Clin Pharmacol Ther</i>. 2001;70(6):525-531.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11753268/pubmed\" target=\"_blank\" id=\"11753268\">11753268</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dionne RA, Yagiela JA, Moore PA, et al, &ldquo;Comparing Efficacy and Safety of Four Intravenous Sedation Regimens in Dental Outpatients,&rdquo; <i>Am Dent Assoc</i>, 2001, 132(6):740-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11433853 /pubmed\" target=\"_blank\" id=\"11433853 \">11433853 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doyle WL and Perrin L, &ldquo;Emergence Delirium in a Child Given Oral Midazolam for Conscious Sedation,&rdquo; <i>Ann Emerg Med</i>, 1994, 24(6):1173-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24363133\"></a>Fernandez A, Lantigua H, Lesch C, et al. High-dose midazolam infusion for refractory status epilepticus. <i>Neurology.</i> 2014;82(4):359-365.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/24363133/pubmed\" target=\"_blank\" id=\"24363133\">24363133</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fragen RJ, &ldquo;Pharmacokinetics and Pharmacodynamics of Midazolam Given via Continuous Intravenous Infusion in Intensive Care Units,&rdquo; <i>Clin Ther</i>, 1997, 19(3):405-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/9220206/pubmed\" target=\"_blank\" id=\"9220206\">9220206</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fraser G, &ldquo;Intranasal Midazolam,&rdquo; <i>Hosp Pharm</i>, 1992, 27:73-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26900382\"></a>Glauser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. <i>Epilepsy Curr</i>. 2016;16(1):48-61. doi:10.5698/1535-7597-16.1.48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/26900382/pubmed\" target=\"_blank\" id=\"26900382\">26900382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hartman ME, McCrory DC, and Schulman SR, &ldquo;Efficacy of Sedation Regimens to Facilitate Mechanical Ventilation in the Pediatric Intensive Care Unit: A Systematic Review,&rdquo; <i>Pediatr Crit Care Med</i>, 2009, 10(2):246-55.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18245435\"></a>Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hughes J, Gill A, Leach HJ, et al, &ldquo;A Prospective Study of the Adverse Effects of Midazolam on Withdrawal in Critically Ill Children,&rdquo; <i>Acta Paediatr</i>, 1994, 83(11):1194-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10507628\"></a>Igartua J, Silver P, Maytal J, Sagy M. Midazolam coma for refractory status epilepticus in children. <i>Crit Care Med</i>. 1999;27(9):1982-1985.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/10507628/pubmed\" target=\"_blank\" id=\"10507628\">10507628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iqbal MM, Sobhan T, Ryals T, et al, &quot;Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,&quot; <i>Psychiatr Serv</i>, 2002, 53(1):39-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11773648/pubmed\" target=\"_blank\" id=\"11773648\">11773648</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, &ldquo;Standard Concentrations of Neonatal Drug Infusions,&rdquo; 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacqz-Algrain E, Daoud P, Burtin P, et al, &ldquo;Placebo-Controlled Trial of Midazolam Sedation in Mechanically Ventilated Newborn Babies,&rdquo; <i>Lancet</i>, 1994, 344(8923):646-50.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8461208\"></a>Johanson GA. Midazolam in terminal care. Am J Hosp Palliat Care. 1993;10(1):13-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/8461208/pubmed\" target=\"_blank\" id=\"8461208\">8461208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson E, Briskie D, Majewski R, et al, &quot;The Physiologic and Behavioral Effects of Oral and Intranasal Midazolam in Pediatric Dental Patients,&quot; <i>Pediatr Dent</i>, 2010, 32(3):229-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/20557707/pubmed\" target=\"_blank\" id=\"20557707\">20557707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&auml;lvi&auml;inen R, &ldquo;Status Epilepticus Treatment Guidelines,&rdquo; <i>Epilepsia</i>, 2007, 48(Suppl 8):99-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/18330014/pubmed\" target=\"_blank\" id=\"18330014\">18330014</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kanto J, &ldquo;Midazolam: The First Water-soluble Benzodiazepine-Pharmacology, Pharmacokinetics and Efficacy in Insomnia and Anesthesia,&rdquo; <i>Pharmacotherapy</i>, 1985, 5(3):138-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/3161005/pubmed\" target=\"_blank\" id=\"3161005\">3161005</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kanto J, Aaltonen L, Himberg JJ, et al, &ldquo;Midazolam as an Intravenous Induction Agent in the Elderly: A Clinical and Pharmacokinetic Study,&rdquo; <i>Anesth Analg</i>, 1986, 65(1):15-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/2934006/pubmed\" target=\"_blank\" id=\"2934006\">2934006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly LE, Poon S, Madadi P, Koren G. Neonatal benzodiazepines exposure during breastfeeding. <i>J Pediatr</i>. 2012;161(3):448-451.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/22504099/pubmed\" target=\"_blank\" id=\"22504099\">22504099</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koitabashi T, Satoh N, Takino Y. Intravenous midazolam passage into breast milk. <i>J Anesth</i>. 1997;11:242-243.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12593465\"></a>Koul R, Chacko A, Javed H, Al Riyami K. Eight-year study of childhood status epilepticus: midazolam infusion in management and outcome. <i>J Child Neurol</i>. 2002;17(12):908-910.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/12593465/pubmed\" target=\"_blank\" id=\"12593465\">12593465</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9196363\"></a>Koul RL, Raj Aithala G, Chacko A, Joshi R, Seif Elbualy M. Continuous midazolam infusion as treatment of status epilepticus. <i>Arch Dis Child</i>. 1997;76(5):445-448.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/9196363/pubmed\" target=\"_blank\" id=\"9196363\">9196363</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kress JP, Pohlman AS, O&rsquo;Connor MF, et al, &ldquo;Daily Interruption of Sedative Infusions in Critically Ill Patients Undergoing Mechanical Ventilation,&rdquo; <i>N Engl J Med</i>, 2000, 342(20):1471-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/10816184/pubmed\" target=\"_blank\" id=\"10816184\">10816184</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1559361\"></a>Kumar A, Bleck TP. Intravenous midazolam for the treatment of refractory status epilepticus. <i>Crit Care Med</i>. 1992;20(4):483&ndash;488.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/1559361/pubmed\" target=\"_blank\" id=\"1559361\">1559361</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kupietzky A and Houpt MI, &ldquo;Midazolam: A Review of Its Use for Conscious Sedation of Children,&rdquo; <i>Pediatr Dent</i>, 1993, 15(4):237-41.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee-Kim SJ, Fadavi S, Punwani I, et al, &quot;Nasal Versus Oral Midazolam Sedation for Pediatric Dental Patients,&quot; <i>J Dent Child (Chic)</i>, 2004, 71(2):126-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/15587094/pubmed\" target=\"_blank\" id=\"15587094\">15587094</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ljungman G, Kreuger A, Andr&eacute;asson S, Gordh T, S&ouml;rensen S. Midazolam nasal spray reduces procedural anxiety in children. <i>Pediatrics</i>. 2000;105(1 Pt 1):73-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/10617707/pubmed\" target=\"_blank\" id=\"10617707\">10617707</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lugo RA, Fishbein M, Nahata MC, et al, &ldquo;Complication of Intranasal Midazolam,&rdquo; <i>Pediatrics</i>, 1993, 92(4):638.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacGilchrist AJ, Birnie GG, Cook A, et al, &ldquo;Pharmacokinetics and Pharmacodynamics of Intravenous Midazolam in Patients With Severe Alcoholic Cirrhosis,&rdquo; <i>Gut</i>, 1986, 27(2):190-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magny JF, Zupan V, Dehan M, et al, &ldquo;Midazolam and Myoclonus in Neonate,&rdquo; <i>Eur J Pediatr</i>, 1994, 153(5):389-90.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Malinovsky JM, Populaire C, Cozian A, et al, &ldquo;Premedication With Midazolam in Children, Effect of Intranasal, Rectal and Oral Routes on Plasma Midazolam Concentrations,&rdquo; <i>Anaesthesia</i>, 1995, 50(4):351-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Massanari M, Novitsky J, and Reinstein LJ, &ldquo;Paradoxical Reactions in Children Associated With Midazolam Use During Endoscopy,&rdquo; <i>Clin Pediatr (Phila)</i>, 1997, 36(12):681-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matheson I, Lunde PK, Bredesen JE, et al, &quot;Midazolam and Nitrazepam in the Maternity Ward: Milk Concentrations and Clinical Effects,&quot; <i>Br J Clin Pharmacol</i>, 1990, 30(6):787-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/2288825/pubmed\" target=\"_blank\" id=\"2288825\">2288825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McMullin ST, Schaiff RA, and Dietzen DJ, &ldquo;Stability of Midazolam Hydrochloride in Polyvinyl Chloride Bags Under Fluorescent Light,&rdquo;<i>Am J Hosp Pharm</i>, 1995, 52(18), 2018-20.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24099896\"></a>Mercadante S, Porzio G, Valle A, et al. Palliative sedation in patients with advanced cancer followed at home: a prospective study. <i>J Pain Symptom Manage</i>. 2014;47(5):860-866.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/24099896/pubmed\" target=\"_blank\" id=\"24099896\">24099896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Midazolam hydrochloride injection solution [prescribing information]. Eatontown, NJ: West-Ward; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Midazolam hydrochloride multidose vials [prescribing information]. Hyderabad, Telangana, India: Gland Pharma Limited; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Midazolam hydrochloride syrup [prescribing information]. Minneapolis, MN: Perrigo; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Midazolam hydrochloride injection [product monograph]. Richmond Hill, Ontario, Canada: Fresenius Kabi Canada; August 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Midazolam hydrochloride preservative-free injection [prescribing information]. Lake Forest, IL: Hospira; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, <i>Miller&rsquo;s Anesthesia</i>, 8th ed, Philadelphia PA: Churchill Livingstone, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16977485\"></a>Morrison G, Gibbons E, and Whitehouse WP, &quot;High-Dose Midazolam Therapy for Refractory Status Epilepticus in Children,&quot; <i>Intensive Care Med</i>, 2006, 32(12):2070-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/16977485/pubmed\" target=\"_blank\" id=\"16977485\">16977485</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray MJ, De Ruyter ML, and Harrison BA, &ldquo;Opioids &amp; Benzodiazepines,&rdquo; <i>Crit Care Clin</i>, 1995, 11(4):849-73.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound, and withdrawal. Canadian Society for Clinical Pharmacology. <i>Can J Clin Pharmacol</i>. 1999;6(2):69-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/10519733/pubmed\" target=\"_blank\" id=\"10519733\">10519733</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nordt SP and Clark RF, &ldquo;Midazolam: A Review of Therapeutic Uses and Toxicity,&rdquo; <i>J Emerg Med</i>, 1997, 15(3):357-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/9258787/pubmed\" target=\"_blank\" id=\"9258787\">9258787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15694567\"></a>Ozdemir D, Gulez P, Uran N, Yendur G, Kavakli T, Aydin A. Efficacy of continuous midazolam infusion and mortality in childhood refractory generalized convulsive status epilepticus. <i>Seizure</i>. 2005;14(2):129-132.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/15694567/pubmed\" target=\"_blank\" id=\"15694567\">15694567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips MS, &ldquo;Standardizing I.V. Infusion Concentrations: National Survey Results,&rdquo; <i>Am J Health Syst Pharm</i>, 2011, 68(22):2176-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/22058104/pubmed\" target=\"_blank\" id=\"22058104\">22058104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11442156\"></a>Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. <i>Epilepsia</i>. 2001;42(3):380&ndash;386.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/11442156/pubmed\" target=\"_blank\" id=\"11442156\">11442156</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"Protus2015\"></a>Protus BM, Kimbrel JM, Grauer PA. <i>Palliative Care Consultant: a reference guide for palliative care. Guidelines for effective management of symptoms</i>. 4th ed. Montgomery, AL; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rita L, Seleny FL, Mazurek A, et al, &ldquo;Intramuscular Midazolam for Pediatric Preanesthetic Sedation: A Double-Blind Controlled Study With Morphine,&rdquo; <i>Anesthesiology</i>, 1985, 63(5):528-31.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Riva J, Lejbusiewicz G, Papa M, et al, &ldquo;Oral Premedication With Midazolam in Paediatric Anaesthesia. Effects on Sedation and Gastric Contents,&rdquo; <i>Paediatr Anaesth</i>, 1997, 7(3):191-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rivera R, Segnini M, Baltodano A, et al, &ldquo;Midazolam in the Treatment of Status Epilepticus in Children,&rdquo; <i>Crit Care Med</i>, 1993, 21(7):991-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Samuelson PN, Reves JG, Kouchoukos NT, et al, &ldquo;Hemodynamic Responses to Anesthetic Induction With Midazolam or Diazepam in Patients With Ischemic Heart Disease,&rdquo; <i>Anesth Analg</i>, 1981, 60(11):802-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/7197492/pubmed\" target=\"_blank\" id=\"7197492\">7197492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Servin F, Enriquez I, Fournet M, et al, &ldquo;Pharmacokinetics of Midazolam Used as an Intravenous Induction Agent for Patients Over 80 Years of Age,&rdquo; <i>Eur J Anaesthesiol</i>, 1987, 4(1):1-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shah I and Deshmukh CT, &ldquo;Intramuscular Midazolam vs Intravenous Diazepam for Acute Seizures,&rdquo; <i>Indian J Pediatr</i>, 2005, 72(8):667-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/16131771/pubmed\" target=\"_blank\" id=\"16131771\">16131771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22579258\"></a>Shergill AK, Ben-Menachem T, Chandrasekhara V, et al. Guidelines for endoscopy in pregnant and lactating women. <i>Gastrointest Endosc</i>. 2012;76(1):18-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/22579258/pubmed\" target=\"_blank\" id=\"22579258\">22579258</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22335736\"></a>Silbergleit R, Durkalski V, Lowenstein D, et al, &quot;Intramuscular Versus Intravenous Therapy for Prehospital Status Epilepticus,&quot; <i>N Engl J Med</i>, 2012, 366(7):591-600.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/22335736/pubmed\" target=\"_blank\" id=\"22335736\">22335736</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silvasi DL, Rosen DA, and Rosen KR, &ldquo;Continuous Intravenous Midazolam Infusion for Sedation in the Pediatric Intensive Care Unit,&rdquo; <i>Anesth Analg</i>, 1988, 67(3):286-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith MT, Eadie MJ, and Brophy TO, &ldquo;The Pharmacokinetics of Midazolam in Man,&rdquo; <i>Eur J Clin Pharmaocl</i>, 1981, 19(4):271-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/6116606/pubmed\" target=\"_blank\" id=\"6116606\">6116606</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spina SP and Ensom MHH, &ldquo;Clinical Pharmacokinetic Monitoring of Midazolam in Critically Ill Patients,&rdquo; <i>Pharmacotherapy</i>, 2007, 27(3):389-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/17316150/pubmed\" target=\"_blank\" id=\"17316150\">17316150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Str&oslash;m C, Rasmussen LS, Steinmetz J. Practical Management of Anaesthesia in the Elderly. <i>Drugs Aging.</i> 2016;33(11):765-777.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/27798767/pubmed\" target=\"_blank\" id=\"27798767\">27798767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Swart EL, de Jongh J, Zuideveld KP, et al, &ldquo;Population Pharmacokinetics of Lorazepam and Midazolam and Their Metabolites in Intensive Care Patients on Continuous Venovenous Hemofiltration,&rdquo; <i>Am J Kidney Dis</i>, 45(2):360-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/15685515/pubmed\" target=\"_blank\" id=\"15685515\">15685515</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Towne AR and DeLorenzo RJ, &ldquo;Use of Intramuscular Midazolam for Status Epilepticus,&rdquo; <i>J Emerg Med</i>, 1999, 17(2):323-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/10195494/pubmed\" target=\"_blank\" id=\"10195494\">10195494</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trouvin J H, Farinotti R, Haberer JP, et al, &ldquo;Pharmacokinetics of Midazolam in Anaesthetized Cirrhotic Patients,&rdquo; <i>Br J Anaesth</i>, 1988, 60(7):762-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/3395535/pubmed\" target=\"_blank\" id=\"3395535\">3395535</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"12536286\"></a>Ulvi H, Yoldas T, Mungen B, Yigiter R. Continuous infusion of midazolam in the treatment of refractory generalized convulsive status epilepticus. <i>Neurol Sci</i>. 2002;23(4):177&ndash;182.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/12536286/pubmed\" target=\"_blank\" id=\"12536286\">12536286</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uygur-Bayrami&ccedil;li O, Dabak R, Kuzucuoglu T, et al, &quot;Sedation With Intranasal Midazolam in Adults Undergoing Upper Gastrointestinal Endoscopy,&quot; <i>J Clin Gastroenterol</i>, 2002, 35(2):133-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/12172357/pubmed\" target=\"_blank\" id=\"12172357\">12172357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Food and Drug Administration. FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. US Food and Drug Administration Web site. <a href=\"https://www.fda.gov/Drugs/DrugSafety/ucm554634.htm\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/ucm554634.htm</a>. Updated April 27, 2017. Accessed May 26, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective gaba(a) receptor modulators? <i>Adv Pharmacol Sci</i>. 2012;2012:1-19.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/22536226/pubmed\" target=\"_blank\" id=\"22536226\">22536226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Votey SR, Bosse GM, Bayer MJ, et al, &ldquo;Flumazenil: A New Benzodiazepine Antagonist,&rdquo; <i>Ann Emerg Med</i>, 1991, 20(2):181-8.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Waring JP, Baron TH, Hirota WK, et al, &ldquo;Guidelines for Conscious Sedation and Monitoring During Gastrointestinal Endoscopy,&rdquo; <i>Gastrointest Endosc</i>, 2003, 58(3):317-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/14528201/pubmed\" target=\"_blank\" id=\"14528201\">14528201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wikner BN, Stiller CO, Bergman U, et al, &quot;Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,&quot; <i>Pharmacoepidemiol Drug Saf</i>, 2007, 16(11):1203-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/17894421/pubmed\" target=\"_blank\" id=\"17894421\">17894421</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10838111\"></a>Yoshikawa H, Yamazaki S, Abe T, Oda Y. Midazolam as a first-line agent for status epilepticus in children. <i>Brain Dev</i>. 2000;22(4):239-242.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/midazolam-drug-information/abstract-text/10838111/pubmed\" target=\"_blank\" id=\"10838111\">10838111</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeltzer LK, Altman A, Cohen D, et al, &ldquo;American Academy of Pediatrics Report of the Subcommittee on the Management of Pain Associated With Procedures in Children With Cancer,&rdquo; <i>Pediatrics</i>, 1990, 86(5 Pt 2):826-31.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9650 Version 235.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709086\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F49990988\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F196443\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F196489\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F196447\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F196467\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F196448\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F196449\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F13134499\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F196415\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F196399\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F50027222\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F196491\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F196419\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14472924\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472925\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F196418\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730634\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F196498\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F196406\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F196422\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F196403\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F196481\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F196408\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F196439\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F196410\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F196425\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F11229384\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F196426\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F196412\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F196402\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F196421\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323409\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F196427\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9650|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=midazolam-patient-drug-information\" class=\"drug drug_patient\">Midazolam: Patient drug information</a></li><li><a href=\"topic.htm?path=midazolam-pediatric-drug-information\" class=\"drug drug_pediatric\">Midazolam: Pediatric drug information</a></li></ul></div></div>","javascript":null}